ASTCT Pharmacy SIG Journal Club - November 2026

The ASTCT Pharmacy SIG November 2026 Journal Club will air on Wednesday, November 18 at 2 p.m. CT/3 p.m. ET. The webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the September Journal Club session, Drs. Hosick and Robida will present two articles related to:

• CRISPR-Cas9 gene-edited allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in acute myeloid leukemia (AML)
• Azacitidine-venetoclax versus induction chemotherapy for the treatment of acute myeloid leukemia (AML)

Presenters & Articles:

Madeleine Hosick, PharmD

PGY-2 Pharmacy Resident

Duke University Hospital

Article: CRISPR−Cas9 CD33-delet hematopoietic cell transp gemtuzumab ozogamicin AML: a phase 1/2 trial

Olivia Robida, PharmD

PGY-2 Pharmacy Resident

The Ohio State University - Wexner Medical Center

Article: Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• List the most common post-hematopoietic cell transplantation (HCT) maintenance strategies and limitations of these standards of care. 
• Discuss the efficacy and clinical implications of Tremtelectogene empogeditemcel (trem-cel) for maintenance in acute myeloid leukemia after allogenic HCT.
• Recognize the risks and toxicities associated with CRISPR-edited gene products in general, and specifically trem-cel in post-HCT patients.
• Review up-front treatment options for newly diagnosed, induction-eligible acute myeloid leukemia (AML) and the rationale for testing azacitidine–venetoclax against standard intensive 7+3 induction chemotherapy.
• Describe the safety and efficacy of azacitidine–venetoclax versus intensive induction chemotherapy for event-free survival in the PARADIGM phase 2 trial.
• Discuss clinical utility and applicability of azacitidine–venetoclax as up-front therapy for induction-eligible AML.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([email protected]). 

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this session will be available soon.